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Abstract 
Many small molecules of food origin may effect human health but lack an adequate 
description of their biological activity. To fill this knowledge gap, a first-line workflow is needed 
to assign putative functions, hierarchize the endpoints to test, and guide wet-lab experiments. In 
this framework, the identification of potential biological targets can be used to probe the activity 
of orphan compounds using a so-called “target fishing” approach. Here, we present a proof of 
concept study using an in silico/in vitro target fishing approach on the fungal secondary metabolite 
atromentin. The procedure relies on a computational screening for activity identification coupled 
with experimental trials for dose-response characterization. Computational results identified 
estrogen receptors and 17-β-hydroxysteroid dehydrogenase as potential targets. Experiments 
confirmed a weak estrogenic activity, supporting the reliability of the procedure. Despite limited 
estrogenicity of atromentin, the proposed inhibition of 17-β-hydroxysteroid dehydrogenase should 
be considered as a source for endocrine disruptive effects. 
 
Keywords: atromentin, target fishing, estrogenic activity, fungal metabolite, activity assignment, 
17-β-hydroxysteroid dehydrogenase  
1. Introduction 
Food may be a source of exposure to many xenobiotics with potential biological or toxic 
activity. Such compounds may be inherently present as food constituents or they may be 
introduced, either voluntarily or not, along the food production chain (Rather, Koh, Paek, & Lim, 
2017). Considering the huge number of compounds occurring in food, an adequate characterization 
of any possible biological/toxic activity is still lacking for many of them. Nevertheless, the overall 
identification of bioactive and toxic molecules in food is crucial to advance the current 
understanding of the effects on human health and wellbeing. In this respect, the understanding of 
small molecules profiling and fingerprinting is getting more and more detailed by taking advantage 
of -omic sciences such as proteomics and metabolomics (e.g. ref. (Scalbert, Brennan, Manach, 
Andres-Lacueva, Dragsted, Draper, et al., 2014)). However, the assignment of biological 
properties to such a wide number of molecules is currently challenging, albeit it is the primal step 
to assess the hazards or benefits to human health. Obviously, the risk assessment of toxicants and 
the assignment of health claims require the collection of a wealth of evidence including data on 
occurrence, exposure, bioavailability, bioaccessibility and both, the chronic and acute effects in 
living organisms. Nevertheless, the use of upstream methods to preliminarily assign a possible 
toxic or biological activity to molecules of interest, which is framed into the hazard/activity 
identification process, may allow a more effective setting up of further experimental 
investigations. Currently, there is an outbreak of novel molecular scaffolds as a result of the efforts 
of the international scientific community in discovering new fungal secondary metabolites, which 
makes the assignment of function an exceptional challenge. Thus, prompt work-flows to timely 
support decision making and to plan effective future investigations need to be implemented. 
In this framework, the identification of the biological targets along with proposing possible 
mechanisms of action may be an effective way to probe the activity of orphan compounds (i.e. 
compounds with poorly characterized activity and/or unknown biological targets). In this regard, 
the so defined “target fishing” is a consolidated approach in medicinal chemistry to discover 
unexpected targets for pharmacologically active molecules. Target fishing is commonly applied to 
investigate the polypharmacology of drugs (Cereto-Massagué, Ojeda, Valls, Mulero, Pujadas, & 
Garcia-Vallve, 2015; Chaudhari, Tan, Huang, & Zhang, 2017), in off-targets identification, and in 
drug repositioning (Delavan, Roberts, Huang, Bao, Tong, & Liu, 2017). Currently, target fishing 
studies mainly rely on proteomic-, genomic- and computational-based approaches (Jung & Kwon, 
2015). In particular, the integrated use of in silico simulations and in vitro trials already proved to 
be effective in target fishing studies and in the bioactivity/toxicity assessment of small molecules 
(Dellafiora, Dall'Asta, & Galaverna, 2018; Scafuri, Varriale, Facchiano, D'Auria, Raggi, & 
Marabotti, 2017).  
In this work, we investigated whether a target fishing approach can be successfully applied 
also in the field of food chemistry and toxicology by investigating the potential activity of poorly 
characterized molecules of food origin. A hybrid in silico/in vitro workflow composed by ligand-
based virtual screening and structure-based molecular modelling studies coupled to experimental 
trials is presented. Atromentin (Figure 1), a fungal metabolite from involutin biosynthesis of 
Paxillus involutus (Braesel, Götze, Shah, Heine, Tauber, Hertweck, et al., 2015) with a poorly 
characterized activity/toxicity (NCBI) was selected as a proof of principle. Atromentin is a low 
molecular weight fungal pigment precursor with a polyphenolic and benzoquinone structure that 
can be found in basidiomycetes mushrooms, including some intended for human consumption (Hu 
& Liu, 2003; Ngoc Quang, Hashimoto, Hitaka, Tanaka, Nukada, Yamamoto, et al., 2003). More 
recently, it was also found as a secondary metabolite produced by the ascomycete Aspergillus 
terreus (Hühner, Backhaus, Kraut, & Li, 2018), pointing to a broader distribution among the fungal 
kingdom. Even though some biological properties have been identified over the years (e.g. 
anticoagulant, apoptotic and antimicrobial activity) (Brewer, Jen, Jones, & Taylor, 1984; Khanna, 
Malone, Euler, & Brady, 1965; Kim & Lee, 2009), the body of evidence collected so far is still 
fragmentary, making atromentin a good candidate for the study we propose. This work identified 
biological targets of potential concern and possible mechanisms of action, extending the 
knowledge on atromentin activity and paving the ground for further investigations. 
 
2. Material and methods 
2.1 In silico modelling 
2.1.1 Data collection and ligand-based virtual screening 
 The atromentin 3D structure was used as template to query a database of compounds with 
known activity and biological targets, aiming at identifying hits with degrees of physico-chemical 
similarities. The database was built using the ligands repository available in the RCSB PDB 
databank (https://www.rcsb.org) (Berman, Westbrook, Feng, Gilliland, Bhat, Weissig, et al., 2000) 
containing all the ligands bound to the proteins deposited in the databank. In particular, all non-
redundant 3D structures of ligands (24,893 entries) were downloaded from the Ligand Expo 
Download page (http://ligand-expo.rcsb.org) in the chemical table file format (sdf; last database 
access in August, 23rd 2017). Considering that atromentin has a molecular weight of 324.3 g/mol, 
all compounds were pre-filtered taking only those with a molecular weight ranging between 200 
and 500 g/mol (15,248 entries were selected). This subset of compounds was used for the ligand-
based virtual screening using the FLAP software (https://www.moldiscovery.com) (Baroni, 
Cruciani, Sciabola, Perruccio, & Mason, 2007). The default software setting was used to create 
the database and virtual screening was performed using the bit string mode to reduce the 
computation time.  
2.1.2 Structure-based molecular modelling 
 The ligand-based virtual screening aimed at sorting the compounds according to the degree 
of similarity to atromentin. Notably, structural similarity may allow different compounds to share 
biological/toxicological endpoints as they may use the common chemical features to interact with 
the same biological targets (vide infra). Therefore, the interaction between atromentin and the 
biological targets of the best hits identified by the virtual screening was thoroughly investigated 
using a structure-based molecular modelling study. The structure-based study relied on the 
pharmacophoric analysis of the ligand binding sites and on docking simulations to investigate the 
molecular details of the ligand-target interaction. 
Model preparations. The models for the alpha and beta isoforms of the estrogen receptor 
(ERα and ERβ, respectively), the 17-β-hydroxysteroid dehydrogenase (HSD) from Curvularia 
lunata and the human Type I HSD were derived from the crystallographic structures deposited in 
the RCSB PDB databank (http://www.rcsb.org) (Berman, et al., 2000) with ID codes 2YJA 
(Phillips, Roberts, Schade, Bazin, Bent, Davies, et al., 2011), 3OLL (Möcklinghoff, Rose, Carraz, 
Visser, Ottmann, & Brunsveld, 2010), 4FJ1 (Cassetta, Stojan, Krastanova, Kristan, Brunskole 
Švegelj, Lamba, et al., 2017) and 3HB5 (Mazumdar, Fournier, Zhu, Cadot, Poirier, & Lin, 2009), 
respectively. All protein structures were processed using the Sybyl software, version 8.1 
(www.certara.com) and the consistency of atom and bond types was checked as described 
previously (Dellafiora, Galaverna, Dall'Asta, & Cozzini, 2015). All co-crystallized ligands were 
removed, except for both 17-β-HSD enzymes that were computed in the holo form with the 
NADPH cofactor.  
Pharmacophoric analysis. The binding site of all models was defined using the Flapsite 
tool of the software FLAP (Baroni, Cruciani, Sciabola, Perruccio, & Mason, 2007) while the GRID 
algorithm (Carosati, Sciabola, & Cruciani, 2004) was used to investigate the corresponding 
pharmacophoric space. The DRY probe was used to describe potential hydrophobic interactions, 
while the sp2 carbonyl oxygen (O) and the neutral flat amino (N1) probes were used to describe 
the hydrogen bond acceptor and donor capacity of the target, respectively. All images were 
obtained using the software PyMol version 1.7 (http://www.pymol.org). 
Docking simulations. The interaction between atromentin and the putative targets was 
investigated with a docking study. The software GOLD (Genetic Optimization for Ligand 
Docking) was chosen as it already showed good performances in computing ligand-target 
interactions and in estimating the activity of ligands (e.g. ref. (Dellafiora, Galaverna, & Dall'Asta, 
2017). In particular, the higher the computational scores, the better the expected capability of 
ligands to arrange favourably within the ligand binding site. Software setting and docking protocol 
reported by Ehrlich (Ehrlich, Dellafiora, Mollergues, Dall'Asta, Serrant, Marin-Kuan, et al., 2015) 
were used. As an exception, the external scoring functions were omitted as the GOLD's internal 
scoring function GOLDScore succeeded in analysing the reference set of compounds (vide infra). 
Specifically, GOLDScore fitness considers the external (protein-ligand complex) and internal 
(ligand only) van der Waals energy, protein-ligand hydrogen bond energy and ligand torsional 
strain energy. In each docking study, the proteins were kept semi-flexible and the polar hydrogen 
atoms were set free to rotate. The ligands were set fully flexible. The maximum number of poses 
to generate for each ligand was set at 50. In all models considered, only the pose with the highest 
GOLDScore fitness was kept for each ligand, according to Dellafiora and co-workers (Dellafiora, 
Galaverna, & Dall'Asta, 2017). Additionally, all analyses were done in triplicate to exclude non-
causative scores assignment as GOLD implements a Lamarckian genetic algorithm that may 
introduce variability in the results.  
2.3 In vitro experiments 
2.3.1 Chemicals and reagents 
 Cell culture media and supplements were purchased from GIBCO Invitrogen (Karlsruhe, 
Germany), Sigma–Aldrich (Schnelldorf, Germany) and SARSTEDT AG & CO (Nuembrecht, 
Germany). 17-β- estradiol was purchased from Sigma-Aldrich (Schnelldorf, Germany), genistein 
from Extrasynthese (Genay, France) and ICI 182,780 from Tocris (Bristol, United Kingdom). 
Atromentin was purified (≥ 99% by HPLC; Figure 1S, Supplementing material) from heterologous 
expression of the P. involutus invA5 gene in Aspergillus oryzae as described below. 
2.3.2 Cell culture 
The estrogen-sensitive human endometrial adenocarcinoma cell line Ishikawa, expressing 
ERα and ERβ was selected for this study (Vejdovszky, Schmidt, Warth, & Marko, 2016) and 
purchased from ECACC (Wiltshire, United Kingdom). Cells were cultivated in Minimum 
Essential Medium (MEM), supplemented with 5% FBS (Fetal Bovine Serum), 1% L-glutamine 
and 1% penicillin/streptomycin under humidified conditions (37 °C, 5% CO2). Experiments were 
performed in cells between passages 5 and 20 with the use of “assay medium”, a phenol red free 
Dulbecco’s Modified Eagle Medium containing the F-12 nutrient solution (DMEM/F-12), 
supplemented with 5% charcoal-dextran stripped foetal bovine serum to ensure low hormone 
levels (Fisher Scientific, Braunschweig, Germany). For all assays, the Ishikawa cells were seeded 
at a density of 15,000 cells/well into a 96 well-plate 24 h before a 48 h incubation. All 
measurements were conducted as technical triplicates and repeated in at least three independent 
cellular preparations (biological replicates). Cells were routinely tested for the absence of 
mycoplasma with the PCR Mycoplasma Test Kit (PanReac AppliChem, Darmstadt, Germany). 
2.3.3 Alkaline phosphatase assay 
To evaluate the estrogenic activity, the transcriptional response of the cells was evaluated 
by measuring the catalytic activity of alkaline phosphatase. The natural estrogen 17-β-estradiol (1 
nM) was tested in parallel as positive control. Solvent (1% DMSO) was used as negative control. 
As an additional control and to confirm that the results of the assay arose from estrogenic stimuli, 
the most effective concentrations of atromentin was co-incubated with 1 µM of the high affinity 
estrogen receptor antagonist ICI 182,780. 
The alkaline phosphatase assay was conducted as previously described by Lehmann and 
co-workers (Lehmann, Wagner, & Metzler, 2006). 15,000 cells/well were seeded in 96-well plates 
and after 48 h of incubation, they were washed three times with PBS, and lysed thermally at −80 °C 
for 20 min. Cell lysates were then incubated at room temperature for five minutes, followed by 
addition of 50 µL of AlP buffer (5 mM 4-nitrophenylphosphate, 1 M diethanolamine, 0.24 mM 
MgCl2, pH 9.8) to each well (5 min). Measurements of absorbance (405 nm) were performed every 
three minutes, for one hour, at 37 °C, on a PerkinElmer Victor3V multiple plate reader. Alkaline 
phosphatase activity was calculated as the slope of the curve obtained by the measurements over 
one hour. Final results were normalized to the solvent control. 
2.4 Recombinant production and purification of atromentin 
A heterologous expression system in A. oryzae was developed for recombinant expression 
of the P. involutus invA5 atromentin synthetase gene. The expression system bases on the 
previously described combination of the terrein biosynthesis regulator TerR and its terrein 
synthase target promoter PterA (Gressler, Hortschansky, Geib, & Brock, 2015). A construct 
containing the terR gene under control of the sugar inducible amylase promoter PamyB and the 
pyrithiamine resistance gene ptrA (Gressler, Hortschansky, Geib, & Brock, 2015) was used for 
transformation of A. oryzae RIB40. Strain OP12 containing a single full-length integration of the 
transcription factor construct was selected as expression platform strain. A synthetic version of the 
P. involutus invA5 gene containing an N-terminal His-tag (Braesel, et al., 2015) was provided by 
D. Hoffmeister (Friedrich-Schiller University Jena, Germany) and used as a template for 
amplification with oligonucleotides invA5_Sm-X_fw (5’- CAT CAC AGC ACC ATG GGC AGC 
AGC CAT CAT CAT CAT C -3’) and invA5_SM-X_rv (5’- ATC ACT GCT GCC ATG GTT 
ACA GAC CAC GAG CTT CGA G -3’) using Phusion Hot Start II polymerase (Thermo 
Scientific). The PCR product was fused by in vitro recombination with an NcoI restricted SM-X 
vector containing a phleomycin resistance cassette (Gressler, Hortschansky, Geib, & Brock, 2015) 
using the InFusion HD cloning kit (Takara). The resulting invA5 expression plasmid was used for 
transformation of the OP12 strain and transformants were regenerated in the presence of 30 µg/mL 
phleomycin. Independent transformants were screened for atromentin production and strain 
OP12_invA5_1 was selected for up-scaled atromentin production. Aspergillus minimal medium 
(Gressler, Hortschansky, Geib, & Brock, 2015) containing 2% soluble starch as inducing carbon 
source and 20 mM glutamine as nitrogen source was used. Eight 50 mL cultures were inoculated 
with 1  106 conidia/mL and incubated for 42 h at 28°C on a rotary shaker. The mycelium was 
removed by filtration over Miracloth filter gauze (Merck) and the combined culture filtrates were 
acidified with formic acid (0.2% final concentration). An XAD-16 resin was regenerated in 
methanol, extensively washed with water and added to the acidified culture filtrate. The mixture 
was shaken for 10 min at 150 rpm to allow binding of atromentin to the resin. The clear supernatant 
was discarded and atromentin was eluted by repeated addition of methanol. Purity of atromentin 
was analysed by HPLC chromatography over an Eclipse XDB-C18 column, 5 μm, 4.6 × 150 mm 
(Agilent) on a Dionex UltiMate3000 HPLC (Thermo Fisher Scientific) as previously described 
(Geib & Brock, 2017). No other contaminating metabolite peaks were observed (Supporting 
materials, Figure 1S). Purified atromentin (about 120 mg) was dried under reduced pressure and 
stored as dried compound until further use. 
2.5 Statistical analysis  
All experiments were performed at least in triplicate (n ≥ 3; at least three independent 
biological replicates, each performed as technical triplicates). Data are expressed as the 
mean ± standard error mean (SEM). Statistical analysis was performed using the Origin Pro 2016G 
software. The data was analysed by one-way ANOVA (α = 0.05), followed by post hoc Fisher’s 
LSD test (α = 0.05). 
 
3. Results and Discussion 
3.1. Overview of the computational target fishing workflow 
The workflow presented in this study aims at assigning function to molecules of interest 
based on the physico-chemical similarities and mechanistic analogies with already characterized 
compounds. The rationale behind this approach relies on the principle that similar compounds may 
compete for the same biological targets. Accordingly, they may have a degree of analogy in 
initiating specific molecular events, as well as in eliciting similar biological effects (McKinney, 
Richard, Waller, Newman, & Gerberick, 2000). Once the reliability of the computational 
performance has been assessed, the in silico workflow presented in this study may serve as a first 
analytical screening tool to identify the possible activity of orphan compounds. In analogy to the 
hazard identification in the risk assessment process, the activity identification consists in 
describing qualitatively the biological effects that orphan compounds might have, without proving 
their actual incidence in vivo. Furthermore, when coupled with in vitro trials, it may provide 
activity characterization in terms of dose-effect response and mode of action. The overall 
workflow of the study is depicted in Figure 2.  
In this work, atromentin was used as a proof of concept. Atromentin 3D structure was used 
as template for a ligand-based virtual screening querying a database of small molecules with 
known activity and already described biological targets. Then, the most similar compounds 
identified by the screening were inspected for the assigned biological targets prioritizing those 
related to either human macromolecules or pathways of sound pharmacological interest. 
Subsequently, the interaction with atromentin was assessed thoroughly at an atomistic level in 
docking studies. Then, in vitro experiments were performed to achieve activity characterization.  
3.2 Computational results 
3.2.1 Ligand-based virtual screening 
The RCSB PDB repository (http://www.rcsb.org) (Berman, et al., 2000) was used to 
generate the database of compounds analysed with the ligand-based virtual screening (the results 
are reported in Table 1S, Supporting material). The PDB archive is a unique worldwide public 
repository of information about the 3D structure of biological macromolecules. It contains more 
than 130,000 structures resolved mainly by X-ray crystallography, NMR spectroscopy and cryo-
electron microscopy. Many macromolecules are in the bound state and therefore their structures 
are available along with the structure of more than 20,000 different low molecular weight 
compounds. The so defined “chemical components” groups a wide number of ligands sensu stricto 
(including enzyme substrates and inhibitors), metal ions and cofactors with known activity and 
well-described dynamics of target interaction. Using atromentin as a template (324.3 g/mol), all 
compounds with molecular weight ranging between 200 and 500 g/mol (15,248 entries in total) 
were used to carry out the ligand-based virtual screening. The screening was done using the FLAP 
software (see material and method for more details) and the output sorted according to the FLAP 
“distance score”, which is an overall estimate of the divergence of compounds from the template 
(atromentin in this case) in terms of physico-chemical properties (the lower the score the more 
similar the compounds are). 
The RCSB PDB archive collects macromolecules from a wealth of organisms from 
different kingdoms. Therefore, all ligands not associated to either human macromolecules or 
pathways of sound pharmacological interest were not taken into account. As shown in Table 1S, 
the best scored compound among those related to human macromolecules was the ligand having 
PDB ID 1W3. It is a polyphenol-derivative compound in complex with the human carrier 
transthyretin. However, the interaction between atromentin and transthyretin was not considered 
for further investigation as the binding to serum transporters can be reasonably expected as non-
specific and it cannot be directly related to the onset of biological stimuli. The next most similar 
compound identified was the polyphenol genistein (PDB ID: GEN) (Figure 1) found bound to ten 
protein-ligand complex structures. Among them, the human estrogen receptor isoforms (ERα and 
ERβ) were considered with highest priority to further investigate the possible interaction with 
atromentin as: i) estrogenic compounds of food origin may be of high relevance for human health; 
ii) a relevant xenoestrogenic activity might be expected on the basis of the molecular similarity 
between atromentin and the synthetic estrogen diethylstilbestrol (Figure 1); iii) the ligand-based 
screening highlighted a degree of similarity between atromentin and matairesinol (Table 1S), 
which is a well-described phytoestrogen (Kiyama, 2016). On this basis, the interaction between 
atromentin and both human ERα and ERβ was further investigated in molecular modelling studies.  
Moreover, the 17-β-hydroxysteroid dehydrogenase (17-β-HSD) from the fungus 
Curvularia lunata was also found among the proteins in the bound state with genistein. This 
enzyme can be used in medicinal chemistry studies in preliminary screenings for possible 
inhibitors of the human 17-β-HSD enzymes (Cassetta, et al., 2017). In addition, genistein is also 
known to inhibit the human Type I 17-β-HSD enzymes (Blomquist, Lima, & Hotchkiss, 2005). 
Therefore, the interaction between atromentin and the fungal orthologous enzyme as well as the 
human Type I 17-β-HSD enzyme was assessed in silico.  
It is worth to mention that many additional targets of interest could have been identified 
scrolling down the rank list of similar compounds. However, the systematic analysis of all possible 
targets requires huge computational resources and therefore was not considered in this proof of 
concept study. Therefore, potential interaction with additional targets not included in this work 
cannot be ruled out.  
3.2.2 Docking studies 
 On the basis of the virtual screening results, the interaction between atromentin and some 
potential biological targets was further assessed by docking studies. As shown previously, docking 
scores may reliably estimate the thermodynamic favours of the host-guest complex formation 
correlating with the energy of binding, with the inhibitory activity of competitive inhibitors (e.g. 
Dellafiora, et al., 2015;) and with the xenoestrogenic activity of low molecular-weight compounds 
(Dellafiora, Warth, Schmidt, Del Favero, Mikula, Fröhlich, et al., 2018; Ehrlich, et al., 2015). 
Nevertheless a fit-for-purpose validation of procedural performances was done to assess the case-
specific reliability. To this end, the capability to successfully compute a set of reference 
compounds in comparison to a benchmark ligand was tested for each target. 
Estrogen receptors. The results of docking simulation on both the ERα and ERβ are 
reported in Table 1. The endogenous ligand 17β-estradiol, the polyphenol genistein and the well-
known synthetic estrogen diethylstilbestrol were selected as reference compounds to test the 
performance of the procedure. Genistein was used as the benchmark for computing the relative 
activity of compounds. The procedure proved to be reliable as: i) it succeeded in calculating the 
binding architecture of the reference compounds (Figure 2S); ii) reference compounds were 
correctly ranked for their relative potency in comparison to the benchmark compound (Table 1). 
Atromentin showed in both ERs a binding architecture resembling that of the other 
compounds with a marked shape overlapping with the synthetic estrogen diethylstilbestrol (Figure 
3A). However, atromentin recorded the lowest scores among all the compounds tested in both ER 
isoform models pointing to a worse fitting into the ligand binding site. The pharmacophoric 
analysis of the ligand pocket and the comparison between the binding pose of atromentin and the 
mode of binding reported for the ER ligands provided a structural explanation. ER ligands need to 
interact with the two polar ends of the pocket (formed by Glu353, Arg394 and His524) and have 
to satisfy the hydrophobic environment with hydrophobic groups (Spyrakis & Cozzini, 2009). 
However, even though the phenolic groups of atromentin may engage the polar ends of the ERs 
pocket, the central benzoquinone moiety bears 4 polar groups that locally reduce the lipophilic 
characteristic of the molecule causing hydrophobic/hydrophilic interferences (Figure 3B).  
On the basis of these results, ERs were identified as putative targets of atromentin and a 
possible estrogenic activity could be expected accordingly. Nevertheless, on account of the low 
scores recorded in both ER isoform and the non-optimal fitting into the ERs, the interaction with 
the ERs can be considered as less favoured than that of the benchmark compound analysed. 
Therefore, a lower efficacy in triggering an ER-dependent stimulus can be expected, as further 
confirmed in vitro (see below).  
17-β-HSDs. According to the results of the virtual-screening, the interaction between 
atromentin and the fungal 17-β-HSD was investigated. In this respect, it has already been reported 
that the procedure used in this study may successfully estimate the inhibitory activity of 
competitive inhibitors (Dellafiora, et al., 2015). Therefore, it may also succeed in estimating the 
possible inhibitory activity of atromentin. In order to assess the procedural performance, genistein 
and the two other polyphenols kaempferol and biochanin A were taken as reference compounds 
since both the geometry of binding and the inhibitory activity have already been assessed (Cassetta, 
et al., 2017). Genistein was accounted as the benchmark compound. The computed binding 
geometry of reference compounds was in strong agreement with the crystallographic data collected 
so far (Figure 3S). In addition, as shown in Table 2, reference compounds were correctly ranked 
for the relative activity in comparison to the benchmark compound genistein. On this basis, the 
procedure could be considered reliable in providing a plausible geometry of binding for atromentin 
and in estimating its potential relative activity in comparison to genistein.  
As shown in Table 2, atromentin recorded a score close to that of genistein pointing to a 
comparable capability to fit into the enzyme pocket. Concerning the geometries of binding, the 
crystallographic data collected so far revealed a unique binding pose for genistein and kaempferol 
with the B ring directed toward the binding site entrance (Figure 3C). Conversely, biochanin A 
may have two possible modes of arranging into the binding pocket: one retraces the mode of 
binding of genistein and kaempferol (the one predicted by the molecular modelling), while the 
other presents an opposite direction of the B ring that is more embedded into the binding site close 
to the nicotinamide moiety of the prostetic group NADPH (Cassetta, et al., 2017). This eventually 
suggests that polyphenols may have alternative modes in arranging within the enzyme binding site. 
Atromentin retraced the binding mode of genistein keeping the same π-π interaction with the side 
chain of Tyr212. However, the longer length of the chemical structure of atromentin caused a more 
pronounced sinking of the aromatic ring towards the bottom of the pocket engaging via hydrogen 
bond of the side chain of Tyr167 (Figure 3D). In addition, atromentin satisfied the pharmacophoric 
fingerprint of the binding site, which consists in a central lipophilic environment with spaces able 
to receive hydrophilic groups on the two sides. Indeed, the central hydrophobic core of the 
molecule is embedded in the lipophilic space, while the polar groups are placed in the hydrophilic 
environment (Figure 3E). On the basis of these results the interaction between atromentin and the 
fungal 17-β-HSD can be considered as possible and a certain degree of inhibitory activity can be 
expected accordingly. It is noteworthy however that the inhibitory activity of genistein towards 
the fungal enzyme is quite weak and therefore, on the basis of computational scores, a mild activity 
can be expected also for atromentin. 
Subsequently, the interaction between atromentin and the human Type I 17-β-HSD was 
assessed in account of: i) the positive interaction between atromentin and the fungal orthologous; 
ii) the similarity found by the virtual screening between atromentin and genistein, which is a known 
inhibitor of the human Type I 17-β-HSD (Schuster, Nashev, Kirchmair, Laggner, Wolber, Langer, 
et al., 2008). Genistein, the strong inhibitor 3-{[(9beta,14beta,16alpha,17alpha)-3,17-
dihydroxyestra- 1,3,5(10)-trien-16-yl]methyl}benzamide (PDB ID E2B) and flavanone were 
selected as reference compounds to assess the procedural performance. Genistein was accounted 
as the benchmark. As seen for the fungal enzyme, the procedure succeeded in calculating the 
geometry of binding (Figure S2) and in ranking the reference compounds in accordance to the 
inhibitory activity reported so far (Table 2).  
As shown in Table 2, atromentin recorded a score higher than genistein pointing to an 
overall better fitting into the pocket. The pharmacophoric fingerprint of the pocket was similar to 
that of the fungal enzyme (i.e. a central lipophilic environment with hydrophilic regions on the 
sides), albeit the hydrophilic regions were found to be less extended. The geometry of binding of 
genistein into the human enzymes has not been resolved yet. However, in accordance to the 
geometry of binding proposed for polyphenols by Schuster and co-workers (Schuster, et al., 2008), 
genistein was found contacting via hydrogen bonds Glu284 with the hydroxyl groups on the A 
ring and the Ser142 with the hydroxyl group on the B ring (Figure 3F). The consistence with the 
geometry of binding previously reported may strengthen further the reliability of the predicted 
geometries. Also an additional contact with Tyr218 was found, while the aromatic parts were 
arranged into the lipophilic environment of the pocket. Similar to genistein, atromentin engaged 
via hydrogen bonds with Glu284 and Tyr218, but not Ser142. In addition, as seen in the fungal 
enzyme, the more pronounced sinking into the pocket allowed atromentin to contact Tyr155 via 
hydrogen bonding (Figure 3G). Also in this case, the hydrophobic aromatic scaffolds were found 
to be embedded in the lipophilic environment, while the polar groups were found mainly arranged 
within a hydrophilic environment. Therefore, atromentin succeeded in fitting the pharmacophoric 
requirements of the Type I human 17-β-HSDs pocket.  
Taking into account the computational score and the pharmacophoric fitting into the 
enzyme pocket, the interaction between the human Type I 17-β-HSD enzyme and atromentin can 
be considered as possible. A degree of inhibitory activity can be hypothesized accordingly. In 
particular, a higher inhibitory activity than genistein might be hypothesized on the basis of the 
higher score recorded. It is worth to note that genistein already has a good inhibitory activity 
towards the human Type I 17-β-HSD in comparison to the other polyphenols tested (Poirier, 2003; 
Schuster, et al., 2008). Notably, the human Type 1 17-β-HSD is a relevant enzyme in human 
physiology as it plays critical role in balancing the conversion of estrone to 17β-estradiol and vice 
versa (Mazumdar, Fournier, Zhu, Cadot, Poirier, & Lin, 2009). Along with the other human 
isoforms, Type 1 17-β-HSD has been accounted in drug development for the therapeutic treatment 
of a number of hydroxysteroid-sensitive pathologies (Poirier, 2003). Therefore, the applied 
workflow identified the possible inhibitory activity towards Type 1 17-β-HSD as an activity to be 
tested with priority in further studies to deepen the possible biological roles of atromentin. 
3.3 Experimental assessment of estrogenic activity  
The in silico prediction of the possible estrogenic activity of atromentin was supported by 
an in vitro assessment of estrogenicity with a reporter gene assay in Ishikawa cells using the 
estrogenic impact on alkaline phosphatase expression as read-out. In particular, the dose-response 
activity of atromentin was assessed at concentrations ranging from 0.05 to 250 µM and compared 
to that of the benchmark compound genistein at concentrations ranging from 0.001 to 1 µM. The 
activity of the endogenous ligand 17β-estradiol (1 nM) was taken as a reference. Both atromentin 
and genistein showed a dose-response effect (Figure 4A). However, no significant activity for 
atromentin was detected below 100 µM, while genistein showed significant response starting from 
0.05 µM (P < 0.001). In addition, the estrogen receptor-dependent activity of atromentin was tested 
by co-incubating the most effective concentration with the ER antagonist ICI 182,780 (1 µM). As 
shown in Figure 4B, the co-incubation was able to significantly suppress the activity of atromentin 
(P < 0.001) supporting the ER-dependent mechanism of action identified by the in silico study. 
On the basis of this result, the mild estrogenic activity of atromentin via the ER-dependent 
mechanism found in silico was confirmed in vitro. 
 
4. Conclusions 
A target fishing study using ligand-based virtual screening and structure-based analysis, 
coupled with in vitro trials, has been presented. In particular, once the reliability of the 
computational procedure was assessed, the workflow allowed the identification of potential 
activities for further testing. However, when coupled with in vitro experiments, the procedure may 
also provide an activity characterization in terms of dose-response effects. The analysis of the 
orphan fungal secondary metabolite atromentin was selected as a proof of principle. Ligand-based 
screening identified several putative biological targets and the interaction with some of those 
relevant for human health had been investigated thoroughly with docking studies. According to 
the computational results, estrogen receptors and 17-β-HSD were identified possible relevant 
targets of atromentin. Therefore, in the framework of activity identification, degrees of 
estrogenicity via ERs activation and inhibition of 17-β-HSD can be expected. The computational 
data on estrogenicity were supported by the in vitro assessment using an alkaline phosphatase 
activity assay in Ishikawa cells, which confirmed the weak potency of atromentin. Nevertheless, 
in spite of the mild activity observed, broader effects on the enzymes that regulate estrogens 
production cannot be excluded on account of the results obtained for 17-β-HSDs. Therefore, in the 
light of deepening possible biological/toxic roles of atromentin in living organisms, the effects on 
estrogen production and regulation, along with those on the estrogen-mediated responses, have to 
be investigated with priority. 
In addition, the results collected proved the procedure reliable in assigning biological 
functions. Accordingly, hybrid in silico/in vitro target fishing studies can be accounted as a 
valuable tool to investigate the unexpected activity of molecules of food origin, as well as to assign 
possible biological targets to orphan compounds. Therefore, we propose this approach as a first-
line analytical tool to widen the current understanding of the bioactive/toxic composition of food 
constituents.  
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Figures and captions 
 
Figure 1. Structures of the molecules mentioned in the work. 
  
  
Figure 2. Schematic representation of the workflow used in the target fishing study. The low-
molecular weight compounds belonging to the so called “chemical components” repository of the 
RCSB PDB archive (https://www.rcsb.org/) are accounted for a ligand-based virtual screening 
study. This first-line screening aims at identifying compounds sharing a degree of physico-
chemical similarity with the query compound atromentin. Each low-molecular weight compound 
occurs as ligand in at least one macromolecule-ligand complex. Therefore, once the most similar 
compounds are identified, the interaction between the respective macromolecular structures and 
atromentin is thoroughly investigated with docking studies. The prediction of the atromentin-target 
interaction may lead to the identification of a potential activity, while the experimental assessment 
will allow characterization of the biological activity. 
  
 Figure 3. Binding geometry of atromentin into the ER pocket (A and B), and atromentin and 
genistein into fungal and human 17-β-HSDs (C-G). Due to the high conservation between ER 
isoforms, only the interaction with the ERα pocket is shown. Proteins are represented in in cartoon 
(A, B, D-G) or in cut surface (C), while ligands and amino acids side chains are represented in 
sticks. Hydrogen bonds are indicated with yellow dashed lines. A. Binding pose of atromentin 
(yellow) overlapping diethylstilbestrol (cyan). The green mesh represents the shape of the binding 
site. B. Binding pose of atromentin. The white mesh indicates the hydrophobic environment of the 
pocket. The red circle highlights the unfavourable arrangement of the polar core of atromentin. C. 
Crystallographic pose of genistein into the fungal enzyme (PDB code 4FJ1; (Cassetta, et al., 
2017)). D. Computational pose of atromentin (yellow) into the fungal enzyme superimposed to the 
crystallographic pose of genistein (white). The ring indicates the molecular region sinking towards 
the bottom of the binding site. E. Binding pose of atromentin in comparison to the pharmacophoric 
fingerprint of the biding site. White, red and blue contours identify regions sterically and 
energetically favourable for hydrophobic, H-bond acceptors and H-bond donor groups, 
respectively. Blue and green rings indicate the position of the polar and hydrophobic regions of 
atromentin, respectively. F. Computed architecture of genistein. G. Computed architecture of 
atromentin. 
  
 Figure 4. Estrogenic activity of atromentin assessed in vitro. A. Estrogenic activity of atromentin 
in comparison to genistein as measured after 48 h of incubation with the AlP assay in Ishikawa 
cells. The graph shows the increase of AlP induction as mean values + SEM of at least 4 
independent experiments related to the effect of the positive control (1 nM E2), which was set to 
100%. Significant differences to the lowest applied concentration of the respective compound were 
calculated by one-way ANOVA, followed by Fisher’s LSD post-hoc testing, and are indicated 
with “*” (P < 0.05), “**” (P < 0.01) or “***” (P < 0.001). 
B. AlP results for 250 µM atromentin, incubated with and without 1 µM ICI 182,780. Results are 
expressed as means + SEM of at least 4 independent experiments. The significant difference 
between those results, which proves its ER-dependency of the observed inductive effect, was 
calculated by Student’s t-test (P < 0.001). 
Supporting materials 
 
 
 
Hybrid in silico/in vitro target fishing to assign function to “orphan” 
compounds of food origin – the case of the fungal metabolite atromentin 
 
Luca Dellafiora1, Georg Aichinger2, Elena Geib3, Leyre Sánchez-Barrionuevo4, Matthias Brock3, 
David Cánovas4, Chiara Dall’Asta1, Doris Marko2,  
 
1  Department of Food and Drug, University of Parma, Via G.P. Usberti 27/A, 43124 Parma, Italy 
2 Department of Food Chemistry and Toxicology, Faculty of Chemistry, University of Vienna, 
Waehringer Str. 38, 1090 Vienna, Austria 
3 Fungal Genetics and Biology Groups, School of Life Sciences, University of Nottingham, 
University Park, NG7 2RD Nottingham, UK 
4 Department of Genetics, Faculty of Biology, University of Sevilla, 41012, Spain  
 
Corresponding author: Chiara Dall’Asta 
Department of Food and Drug, University of Parma, Via G.P. Usberti 27/A, 43124 Parma, 
Italy 
Table 1S. Results of the ligand-based virtual screening 
Distance score Ligand ID Ligand name Related structure ID  
0.12  1G4 (3S,6S)-3,6-bis(4-hydroxybenzyl)piperazin-2-one 4IPS Cytochrome P450 from Mycobacterium tuberculosis 
0.13  69T 4-(5-((4-hydroxyphenyl)amino)-1H-pyrazol-3-yl)phenol 5IBJ Cytochrome P450 from M. tuberculosis 
0.14  KRA 1-(4-hydroxyphenyl)-4-phenyl-butane-2,3-dione Record not available ---  
0.14  1W3 
7-hydroxy-3-[(E)-2-(4-hydroxy-3,5-dimethylphenyl)ethenyl]-4-
methyl-2H-chromen-2-one 
4KY2 Transthyretin complex from Homo sapiens 
0.15  1G7 
(3S,6S)-3-(3,4-dihydroxybenzyl)-6-(4-hydroxybenzyl)piperazine-
2,5-dione 
4IPW Cytochrome P450 from M. tuberculosis 
0.16  GEN Genistein 5KDA Aromatic prenyltransferase from Aspergillus terreus 
   5AUZ Death-associated protein kinase 1 from H. sapiens 
   5AV4 Death-associated protein kinase 1 from H. sapiens 
   4FJ1 17-β-HSD from Curvularia lunata 
   3KGT Transthyretin complex from H. sapiens 
   3KGU Transthyretin complex from H. sapiens 
   2QA8 ERα from H. sapiens 
   1X7J ERβ from H. sapiens 
   1X7R ERα from H. sapiens 
   1QKM ERβ from H. sapiens 
0.16  1CQ 4,4'-{3-[(4-hydroxyphenyl)amino]-1H-pyrazole-4,5-diyl}diphenol 4KTL Cytochrome P450 from M. tuberculosis 
0.16  MAX Matairesinol 2BGM 
Secoisolariciresinol Dehydrogenase from Podophyllum 
peltatum 
0.16  RP4 
(1R,4R,5R)-1,4,5-trihydroxy-3-(3-phenylsulfanylphenyl)cyclohex-2-
ene-1-carboxylic acid 
2CJF Type II dehydroquinase from Streptomyces coelicolor 
0.16  64O N-(4-{[4'-(carbamoylamino)-6-hydroxybiphenyl-3-yl]oxy}-3,5-
dichlorophenyl)propanamide 
5HK9 CFTR inhibitory factor from Pseudomonas aeruginosa 
Note → The ten top scored ligands are shown. The records related to either relevant macromolecules and pathway of sound pharmacological interest are underlined 
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 0 
Purified atromentin from heterologous invA5 expression in Aspergillus oryzae OP12. 1 
An HPLC analysis was performed to test the purity of atromentin purified from the culture 2 
broth of A. oryzae OP12. The methanolic fraction was loaded on an Eclipse XDB-C18 column and 3 
the absorption spectrum was recorded at 254 nm. As shown in Figure 1S, atromentin elutes at 9.6 4 
min and shows its typical UV/Vis spectrum. Only very minor impurities were observed and based 5 
on this analysis the fraction was judged as ≥ 99% pure. 6 
 7 
Figure 1S: HPLC analysis of purified atromentin by reverse phase chromatography over an 8 
Eclipse XDB-C18 column. (A) Chromatogram recorded at 254 nm. (B) UV/Vis spectrum of 9 
atromentin. 10 
11 
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Comparison between computational geometries of binding and crystallographic poses of 12 
compounds  13 
To check the procedural reliability in predicting the geometries of binding, the computed 14 
poses were compared to those obtained in crystallographic studies. As shown in Figure 2S and 3S, 15 
all calculated geometries of binding were found to be consistent with the crystallographic poses, 16 
confirming the procedural reliability.  17 
 18 
Figure 2S. Comparison between the computational geometries of binding (yellow) and the 19 
crystallographic poses (white) of 17β-estradiol (A), genistein (B) and diethylstilbestrol (C) into 20 
the ER ligand binding pocket. All ligands and side chain residues are represented in stick while 21 
the protein is shown in cartoon. The green mesh retraces the shape of the binding site. The 22 
crystallographic pose of ligands derived from the crystallographic ERα structure with PDB code 23 
2YJA. The PDB codes used for comparison were 2YJA [24], 1X7R [51] and 3ERD [52], 24 
respectively.  25 
  26 
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 27 
Figure 3S. Comparison between the computational geometries of binding (yellow) and the 28 
crystallographic poses (white) of genistein (A), biochanin A (B) and kaempferol (C) into the 29 
pocket of 17-β-HSD enzymes from Curvularia lunata (A, B and C) or Homo sapiens (D). All 30 
ligands are shown in sticks while proteins are represented in cartoon. The crystallographic pose of 31 
ligands derived from the crystallographic 17-β-HSD structures with PDB codes 4FJ1, 4FJ2, 32 
3QWH [26] and 3HB5 [27], respectively 33 
 34 
Reference not reported in the main text  35 
51. Manas ES, Xu ZB, Unwalla RJ, Somers WS. Understanding the selectivity of genistein for 36 
human estrogen receptor-beta using X-ray crystallography and computational methods. 37 
Structure. 2004 Dec;12(12):2197-207 38 
52. Shiau AK, Barstad D, Loria PM, Cheng L, Kushner PJ, Agard DA, Greene GL. The structural 39 
basis of estrogen receptor/coactivator recognition and the antagonism  of this interaction 40 
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